Condition
Fallopian Tube Cancers clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Fallopian Tube Cancers clinical trials that are recruiting, at sites in 10 countries (most in United States (2), Australia (1), Belgium (1)). By phase: Phase 2 (2), Phase 1/2 (1), Phase 2/3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 10Countries
Newest Fallopian Tube Cancers clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| PARP inhibitor with or without an angiogenesis inhibitor for HRD advanced ovarian, fallopian-tube, or primary peritoneal cancer | Phase 2/3 | Minsk, Lesnoy | Recruiting | Mar 16, 2026 |
| Aitua plus Nab-Paclitaxel and Carboplatin before surgery for advanced high-grade serous ovarian cancer | Phase 2 | Beijing, Beijing Municipality | Recruiting | Feb 25, 2026 |
| Giving TORL-1-23 with chemotherapy before initial surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer | Phase 1/2 | Fullerton, California and 6 other locations | Recruiting | Jan 7, 2026 |
| Mirvetuximab soravtansine for platinum-resistant high-grade ovarian, fallopian tube, and primary peritoneal cancer with high folate receptor-alpha | Phase 2 | Sarasota, Florida and 51 other locations | Recruiting | Nov 12, 2024 |
All recruiting trials (4)
-
PARP inhibitor with or without an angiogenesis inhibitor for HRD advanced ovarian, fallopian-tube, or primary peritoneal cancer
This trial will test whether adding the angiogenesis drug bevacizumab to a PARP inhibitor helps people with homologous recombination deficient (HRD) stage III–IV ovarian, fallopian-tube, or primary peritoneal cancer.
-
Aitua plus Nab-Paclitaxel and Carboplatin before surgery for advanced high-grade serous ovarian cancer
This trial tests whether adding the PD-1/CTLA-4 bispecific antibody Aitua to standard neoadjuvant chemotherapy helps achieve complete tumor removal before interval debulking surgery in newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer patients who are not expected to be debulked to no visib
-
Giving TORL-1-23 with chemotherapy before initial surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer
This study will test whether adding TORL-1-23 to standard paclitaxel and carboplatin before initial surgery helps women with advanced (FIGO III/IV) ovarian, fallopian tube, or primary peritoneal cancer whose tumors are CLDN6-positive.
-
Mirvetuximab soravtansine for platinum-resistant high-grade ovarian, fallopian tube, and primary peritoneal cancer with high folate receptor-alpha
This trial tests whether intravenous mirvetuximab soravtansine helps people with platinum-resistant high-grade ovarian, fallopian tube, or primary peritoneal cancer whose tumors have high folate receptor-alpha.
Related topics
Quick answers
How many Fallopian Tube Cancers clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in United States (2 trials), Australia (1 trial), Belgium (1 trial), France (1 trial), Poland (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1/2: 1, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.